Denton CP, et al. - Efficacy as well as the safety of selexipag (an oral, selective IP prostacyclin receptor agonist) was assessed in patients with systemic sclerosis (SSc)-related Raynaud's phenomenon (RP). No reduction was evident in the number of RP attacks among those who received selexipag vs placebo. In addition, safety profile of selexipag, as reported in this study, was similar to that previously reported. These data offer essential information regarding the feasibility of electronic diary (eDiary) reporting of RP attacks in clinical trials.